Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190019/S043

Ranger Paclitaxel-Coated Balloon Catheter

BOSTON SCIENTIFIC CORPORATION · Decision date Aug 4, 2026

FDA DECISIONP190019/S043

What did the FDA approve?

FDA records P190019/S043 as a supplement to PMA P190019, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 4, 2026.

FDA approval order statement

Approval for a matrix expansion of the Ranger Paclitaxel-Coated PTA Balloon Catheter (P190019) to include the Ranger 035 Paclitaxel-Coated PTA Balloon Catheter, a 0.035-inch guidewire compatible line extension.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Aug 4, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P190019/S043
Regulatory pathway
PMA supplement
Product code
ONU
Decision code
APPR
Decision date
Aug 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.

Product code
ONU
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190019/S039 · Related supplement

    Ranger Paclitaxel-Coated PTA Balloon Catheter

  2. P190019/S041 · Related supplement

    Ranger Paclitaxel-Coated PTA Balloon Catheter

  3. P190019/S042 · Related supplement

    RANGER Paclitaxel-Coated PTA Balloon Catheter

  4. P190019/S040 · Related supplement

    Ranger Paclitaxel-Coated PTA Balloon Catheter

  5. P190019/S043 received

    Application receipt date recorded by FDA.

  6. P190019/S043 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P190019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190019

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 24, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMar 12, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementApr 24, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementMay 1, 2026FDA

Explore the linked device profile

Other records with product code ONU

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
Three Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records